HK1075417A1 - Renal cell carcinoma treatment - Google Patents

Renal cell carcinoma treatment

Info

Publication number
HK1075417A1
HK1075417A1 HK05109749.0A HK05109749A HK1075417A1 HK 1075417 A1 HK1075417 A1 HK 1075417A1 HK 05109749 A HK05109749 A HK 05109749A HK 1075417 A1 HK1075417 A1 HK 1075417A1
Authority
HK
Hong Kong
Prior art keywords
cell carcinoma
renal cell
carcinoma treatment
treatment
renal
Prior art date
Application number
HK05109749.0A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1075417A1 publication Critical patent/HK1075417A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK05109749.0A 1999-04-08 2005-11-02 Renal cell carcinoma treatment HK1075417A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
HK1075417A1 true HK1075417A1 (en) 2005-12-16

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01102198A HK1032533A1 (en) 1999-04-08 2001-03-26 Renal cell carcinoma treatment.
HK05109749.0A HK1075417A1 (en) 1999-04-08 2005-11-02 Renal cell carcinoma treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK01102198A HK1032533A1 (en) 1999-04-08 2001-03-26 Renal cell carcinoma treatment.

Country Status (24)

Country Link
EP (2) EP1535623B1 (xx)
JP (2) JP3712914B2 (xx)
CN (1) CN1367702A (xx)
AR (1) AR029160A1 (xx)
AT (2) ATE296638T1 (xx)
AU (2) AU777406B2 (xx)
BR (1) BR0009644A (xx)
CA (1) CA2303752A1 (xx)
CO (1) CO5170412A1 (xx)
CY (1) CY1108919T1 (xx)
DE (2) DE60020442T2 (xx)
DK (2) DK1043025T3 (xx)
ES (2) ES2319777T3 (xx)
HK (2) HK1032533A1 (xx)
HU (1) HU230271B1 (xx)
MX (1) MXPA00003401A (xx)
MY (1) MY155221A (xx)
NO (1) NO328983B1 (xx)
NZ (1) NZ514629A (xx)
PE (1) PE20010026A1 (xx)
PT (2) PT1535623E (xx)
TW (2) TW200526243A (xx)
WO (1) WO2000061174A2 (xx)
ZA (1) ZA200108169B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
HU230271B1 (hu) * 1999-04-08 2015-11-30 Merck Sharp & Dohme Corp Pegilezett alfa-interferon alkalmazása vesesejt-karcinóma kezelésére

Also Published As

Publication number Publication date
TWI310314B (en) 2009-06-01
DK1535623T3 (da) 2009-04-27
HUP0200781A3 (en) 2002-09-30
ES2319777T3 (es) 2009-05-12
PT1043025E (pt) 2005-09-30
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
WO2000061174A2 (en) 2000-10-19
ATE419002T1 (de) 2009-01-15
AR029160A1 (es) 2003-06-18
DE60041291D1 (de) 2009-02-12
DK1043025T3 (da) 2005-07-04
CY1108919T1 (el) 2014-07-02
HUP0200781A2 (en) 2002-08-28
EP1535623A1 (en) 2005-06-01
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1043025B1 (en) 2005-06-01
BR0009644A (pt) 2002-01-08
ES2239953T3 (es) 2005-10-16
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
CN1367702A (zh) 2002-09-04
DE60020442D1 (de) 2005-07-07
PT1535623E (pt) 2009-03-19
DE60020442T2 (de) 2006-05-04
AU777406B2 (en) 2004-10-14
AU2004242454B2 (en) 2007-02-15
AU2004242454A1 (en) 2005-01-20
JP2000319196A (ja) 2000-11-21
HK1032533A1 (en) 2001-07-27
NO328983B1 (no) 2010-07-05
MY155221A (en) 2015-09-30
NO20014851L (no) 2001-12-07
ZA200108169B (en) 2003-01-06
NZ514629A (en) 2004-02-27
PE20010026A1 (es) 2001-02-05
CA2303752A1 (en) 2000-10-08
ATE296638T1 (de) 2005-06-15
JP2001288110A (ja) 2001-10-16
JP3712914B2 (ja) 2005-11-02
AU4204400A (en) 2000-11-14
WO2000061174A3 (en) 2001-01-25
TW200526243A (en) 2005-08-16
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
GB9918958D0 (en) Filter
HK1147221A1 (zh) 奶泵
IL181414A0 (en) Cell regeneration
GB9904905D0 (en) Cells
HK1075417A1 (en) Renal cell carcinoma treatment
GB9925992D0 (en) Filter
GB9907330D0 (en) Filter
DE50015927D1 (en) Chen
CA88451S (en) Carafe
GB9911889D0 (en) Filter
EP1128451A4 (en) CELL
GB9914798D0 (en) Ensure
GB9917564D0 (en) Improvements in refining
GB2355348B (en) Improvements in connectors
ZA983455B (en) Treatment of renal cell carcinoma
GB9912631D0 (en) Cell counter
GB0027081D0 (en) Solution
GB9907564D0 (en) Filter
GB9917130D0 (en) Treating cells
TW382894U (en) Improved water filter
IL144237A0 (en) Organoprotective solutions
GB9908683D0 (en) Cells
PL109398U1 (en) Drainage cradle
GB9916400D0 (en) Cell line
AU137917S (en) Aqua level

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170406